Dasatinib Powder CAS 302962-49-8 Raw Materials

CAS:302962-49-8

MF: C22H26ClN7O2S

MW: 488.01

EINECS: 801-607-0

Specification​: 99% min Dasatinib 

Sample: Dasatinib Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Dasatinib Powder Usage and Synthesis.

Dasatinib Powder (Dasatinib), alias Sprycel, is an off-white to yellow solid chemical. Clinically Dasatinib Raw Materials is primarily used to treat resistance to imatinib mesylate.

Dasatinib Powder is used to treat adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in the chronic. Dasatinib Powder is used to treat adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in the chronic, accelerated and acute phases (acute granulomatous and acute lytic) who are resistant, or intolerant, to imatinib mesylate.

Uses and functions of Dasatinib Powder.

Dasatinib Powder is used to treat adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in the chronic, accelerated and acute phases (acute granulomatous and acute lytic) who are resistant, or intolerant, to imatinib mesylate.

Dasatinib is an oral, potent inhibitor of oncogenic kinases that blocks signals for accelerated replication of cancer cells. In May 2009, the US Food and Drug Administration (FDA) officially approved dasatinib for marketing and clinical use in the treatment of chronic myeloid leukaemia (CML) in all stages, chronic myeloid leukaemia that is resistant or intolerant to treatment regimens including imatinib mesylate , Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ALL) and solid tumour patients.

Dasatinib Powder is indicated for the treatment of chronic myeloid leukaemia that is resistant or intolerant to treatment regimens including imatinib mesylate.

Pharmacological Effects of Dasatinib Powder.

Dasatinib is a protein kinase inhibitor that inhibits BCR-ABL kinases and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor, for the clinical treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) that is resistant or intolerant to imatinib mesylate. Adult patients with chronic, accelerated and acute phases (acute granulomatous and acute lytic).

• 1. Dasatinib is a protein kinase inhibitor that inhibits BCR-ABL kinases and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor. Dasatinib is a potent, subnanomolar inhibitor of BCR-ABL kinases with strong activity at concentrations of 0.6-0.8 nM. It binds to both the inactive and active conformations of the BCR-ABL enzyme.

• 2. In in vitro studies, dasatinib was active in leukaemia cell lines expressing various imatinib-sensitive and resistant diseases. The results of these non-clinical studies suggest that dasatinib can overcome imatinib resistance caused by: BCR-ABL overexpression, mutations in the BCR-ABL kinase region, activation of other signalling channels including SRC family kinases (LYN, HCK), and overexpression of multidrug resistance genes. In addition, dasatinib inhibited SRC family kinases at sub-nanomolar concentrations.

• 3. In a separate in vivo trial using a murine CML model, dasatinib was able to prevent progression of chronic-phase CML to the acute phase while prolonging the survival of tumour-bearing mice (derived from patient CML cell lines growing at different sites, including the central nervous system).